Can patients develop neutralising antibodies to factor IX during treatment with albutrepenonacog alfa (Idelvion)?

Yes, neutralising antibodies (inhibitors) to factor IX have been reported during albutrepenonacog alfa (Idelvion) treatment for haemophilia B, and patients should be monitored after repeated treatment using appropriate biological testing.